登录 | 注册    关注公众号  
微信公众号
搜索
 > 【VEGF189】

VEGF189信息

英文名称:Vascular endothelial growth factor A
中文名称:血管内皮生长因子A
靶点别称
上市药物数量:35
临床药物数量:63
最高研发阶段:批准上市

VEGF189产品咨询

* 此表格只用于收集产品需求咨询,所有信息将严格保密。
                   
ACRO质量管理体系
 
评论(0)
 

VEGF189 分子别名

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

VEGF189 分子背景

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. Mature human VEGF189 shares 88% aa sequence identity with mouse VEGF188. VEGF189 binds to heparan sulfate both on the cell surface and in the extracellular matrix (ECM) where it retains bioactivit. Furthermore, VEGF189 interacts with various receptors including VEGF R1, VEGF R2, Neuropilin-1, and Integrins aVb3, aVb5, a3b1, and a5b1.

VEGF189 前沿进展

VEGF189上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

VEGF189临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定